Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human hepatic CYP2E1 expression during development.

Elizabeth K Johnsrud1, Sevasti B Koukouritaki, Karthika Divakaran

  • 1Birth Defects Research Center, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

The Journal of Pharmacology and Experimental Therapeutics
|September 23, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phosphorylation of distal C-terminal residues promotes TRPV4 channel activation in response to arachidonic acid.

The Journal of biological chemistry·2025
Same author

A single F153Sβ3 mutation causes constitutive integrin αIIbβ3 activation in a variant form of Glanzmann thrombasthenia.

Blood advances·2023
Same author

Bringing Big Data to Bear in Environmental Public Health: Challenges and Recommendations.

Frontiers in artificial intelligence·2020
Same author

Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids.

Toxicological sciences : an official journal of the Society of Toxicology·2020
Same author

Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans.

Toxicological sciences : an official journal of the Society of Toxicology·2019
Same author

A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes.

Chemical research in toxicology·2019

Human CYP2E1 enzyme expression develops significantly from fetal stages through infancy. Infants under 90 days old show reduced clearance of certain drug substrates due to lower CYP2E1 levels.

Area of Science:

  • Pharmacology and Toxicology
  • Developmental Biology
  • Biochemistry

Background:

  • Cytochrome P450 2E1 (CYP2E1) is crucial for metabolizing various xenobiotics.
  • Developmental changes in CYP2E1 expression can alter drug efficacy and toxicity.
  • Previous studies on CYP2E1 expression during human development yielded conflicting results.

Purpose of the Study:

  • To accurately quantify human hepatic CYP2E1 content across fetal and postnatal developmental stages.
  • To resolve discrepancies in existing literature regarding CYP2E1 developmental expression.
  • To assess the impact of CYP2E1 developmental changes on xenobiotic metabolism.

Main Methods:

  • Human hepatic microsomes were analyzed from fetal (8-37 weeks) and postnatal (1 day-18 years) samples.

Related Experiment Videos

  • CYP2E1 content was measured using immunodetection techniques.
  • Statistical analyses, including ANOVA and linear regression, were employed to evaluate age-related changes and variations.

    • Main Results:

    • CYP2E1 was detectable in late-trimester fetal liver samples, with expression increasing significantly from the second to third trimester.
    • Postnatal CYP2E1 levels were low in neonates, increased by 31-90 days of age, and remained stable in older individuals.
    • Significant inter-individual variability in CYP2E1 content was observed across all age groups, particularly in neonates.

    Conclusions:

    • Human CYP2E1 is expressed in the fetal liver, with significant developmental upregulation postnatally.
    • Infants younger than 90 days exhibit reduced CYP2E1 activity, potentially leading to decreased clearance of CYP2E1 substrates.
    • Understanding these developmental changes is critical for predicting xenobiotic effects in pediatric populations.